Kymera Therapeutics (KYMR) Depreciation & Amortization (CF) (2019 - 2026)

Kymera Therapeutics (KYMR) has 8 years of Depreciation & Amortization (CF) data on file, last reported at $2.0 million in Q1 2026.

• Depreciation & Amortization (CF) for Q1 2026 came in at $2.0 million, down 1.27% year-over-year; the trailing twelve-month figure through Mar 2026 was $8.3 million (up 4.11% YoY), and the FY2025 annual result was $8.3 million, up 12.75% from the prior year.
• Depreciation & Amortization (CF) steadied at $2.0 million in Q1 2026 per KYMR's latest filing, from $2.0 million in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $2.1 million in Q3 2025 and troughed at $687000.0 in Q1 2022.
• A 5-year average of $1.4 million and a median of $1.5 million in 2024 frame the typical range for Depreciation & Amortization (CF).
• The sharpest annual moves came in 2024 and 2026: Depreciation & Amortization (CF) soared 123.01% in 2024, then retreated 1.27% in 2026.
• A 5-year view of Depreciation & Amortization (CF) shows it stood at $818000.0 in 2022, then advanced by 8.92% to $891000.0 in 2023, then soared by 123.01% to $2.0 million in 2024, then grew by 2.26% to $2.0 million in 2025, then slipped by 0.49% to $2.0 million in 2026.
• Business Quant data shows KYMR's Depreciation & Amortization (CF) at $2.0 million in Q1 2026, $2.0 million in Q4 2025, and $2.1 million in Q3 2025.